ASTX030 Trial
Phase 2/3
236
about 8 years
18+
24 sites in CA, CT, FL +12
About this study
Researchers are testing a new treatment, ASTX030 (cedazuridine + azacitidine), for people with certain types of blood cancers. The trial will involve different phases to determine the best way to use this treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ASTX030 (cedazuridine + azacitidine)
- 2.Take Azacitidine
- 3.Take Cedazuridine
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
azacitidine, venetoclax
injection, subcutaneous, oral
Primary: Phase 1 Combination Therapy: Cmax of Venetoclax Without ASTX030, Phase 1 Combination Therapy: Maximum Plasma Concentration (Cmax) of Venetoclax With ASTX030, Phase 1 Combination Therapy: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Phase 1 and 2 Combination Therapy: Complete Response (CR) Rate as Assessed by the Investigator, Phase 1, 2 and 3 Monotherapy: Total Cycle Area Under the Curve (AUC) From 0 to 24 Hours (AUC0-24) Exposures
Secondary: Phase 1 Combination Therapy: AUC of SC Azacitidine and Venetoclax, Phase 1 Combination Therapy: AUC of Venetoclax, Azacitidine, and Cedazuridine, Phase 1 Combination Therapy: Cmax of SC Azacitidine and Venetoclax, Phase 1 Combination Therapy: Cmax of Venetoclax, Azacitidine, and Cedazuridine, Phase 1 Combination Therapy: Tmax of Venetoclax, Azacitidine, and Cedazuridine, Phase 1 and 2 Combination Therapy: CR and Complete Response with Incomplete Hematologic Recovery (CRi) Rate, Phase 1 and 2 Combination Therapy: CR and Complete Response with Partial Hematologic Recovery (CRh) Rate, Phase 1 and 2 Combination Therapy: Cmax of Azacitidine, Cedazuridine and Cedazuridine-epimer
Oncology